<DOC>
	<DOC>NCT00396721</DOC>
	<brief_summary>The purpose of this study is to test in a pilot trial the efficacy and tolerance of sirolimus oral (at low doses) in patient to treat poor-prognosis IgA Nephropathy.</brief_summary>
	<brief_title>Sirolimus Therapy for Poor Prognosis Immunoglobulin A Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis, IGA</mesh_term>
	<mesh_term>Glomerulonephritis</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Age 18 to 70 and with capacity to grant informed consent Biopsyproven IgA nephropathy by means of standard immunohistochemical and morphological criteria Renal biopsy in the in the 3 months prior to randomization date Absence of known hepatic, cardiac, pulmonary or intestinal disease Glomerular filtrate estimated by CockcroftGault, more than 30 ml/min Any of the following clinical states: a) High blood pressure defined as systolic blood pressure higher than 140 mmHg or diastolic blood pressure higher than 90 mmHg associated with proteinuria between 0.31 g/day and/or microhematuria. b) Proteinuria higher than 1g/day Women of childbearing age will follow a suitable contraceptive method, and a negative pregnancy test will be needed before inclusion in the study Serology positive for HIV or hepatitis B infection (defined as positive for the HbsAg antigen) or hepatitis C infection (defined as viral RNA detection) Treatment with steroids or immunosuppressors in the two previous years Evidence of active infection at the time of inclusion in the study Pregnancy or breastfeeding at the time of inclusion in the study Estimated glomerular filtration &lt; 30 ml/min, bilirubin &gt; 2 mg/dl, or ALT or AST two times higher than the normal upper limit Diabetes Mellitus, defined as patients treated with insulin or oral antidiabetics or glycemias higher than 140 mg/dl in two or more episodes Poor control of high blood pressure (defined as systolic blood pressure greater than 160 mm Hg or diastolic blood pressure greater than 100 mm Hg, taking 3 or more antihypertensives) or evidence or suspicion of renovascular disease Thrombocytopenia less than 100,000 /mm3 or total neutrophil value lower than 2000 /mm3 or triglycerides value &gt; 400 mg/dL (4.6 mmol/L) or cholesterol &gt; 300 mg/dL (7.8 mmol/L) or LDL &gt; 200 mg/dL IgA nephropathy systemic forms, i.e., Sch√∂nleinHenoch purpura, IgA nephropathy secondary forms, postrenal transplant IgA nephropathy recurrences, cases presented in the form of rapidly progressive renal failure and cases with the presence of cellular crescents in more than 50% of the glomeruli will be excluded History of cancer in the previous 5 years,exception of skin basocellular carcinoma and uterine in situ carcinoma (completely removed both of them) Know intolerance to Sirolimus or macrolides</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Nephropathy, IGA</keyword>
	<keyword>Pilot trial</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>Rapamune</keyword>
</DOC>